Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Brandon Buttons who wrote (975)	9/13/1999 8:43:00 PM
From: Mass D.	Respond to of 2515

What a steamroller

To: Brandon Buttons who wrote (975)	9/14/1999 1:45:00 AM
From: Gordon James	Read Replies (1) \| Respond to of 2515

Brandon, I believe you may have misunderstood what JEB was getting at in his post. I think you might get a clearer picture of what he meant from reviewing the following company press release, from April 14, 1999: imclone.com Now try his comments with a few added words for clarity: They must be getting ready to announce the <initiation of human> pancreatic trials. It's overdue according to their April pre-clinical trial results. It <initiation of the new trials> was suppose to be in that quarter and the <pre-clinical> results <reported in the April press release> were fantastic. (IMO) Put that way, I don't have much trouble with what he's saying, pancreatic trials could be initiated at any time according to stated company intentions, and the pre-clinical results show us that pancreatic may be an exciting opportunity for this drug. I don't mean to speak for anyone else - just wanted to point out that since I was familiar with that press release, JEB's comments didn't strike me as attempted hype, just poorly worded. Interestingly, the most recent vibes we've gotten from the company (as reported recently by Jim McCamant of MTSL) are that colorectal trials are on the way, with no mention lately of new trials for pancreatic. Perhaps there's been a change in focus for the company, perhaps trials for both are on the way... I've been meaning to contact IR to ask this question, will post the answer once I get it. Gordon